The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed New Long Term Incentive Plan

11 Oct 2010 16:00

RNS Number : 2047U
PuriCore Plc
11 October 2010
 



PuriCore plc  

Proposed New Long Term Incentive Plan and Proposed Amendment to the Existing Option Plan and Notice of General Meeting

 

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 11 October 2010 - PuriCore plc (LSE: PURI) ("PuriCore" or the "Company"), the water-based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces that it is proposing a new Long Term Incentive Plan ("LTIP") and an amendment to the Company's Executive Omnibus Incentive Plan (the "Option Plan").

 

A circular is expected to be posted today to Shareholders by the Company that contains details of the LTIP and the associated proposed change to the Option Plan (the "Circular"). The Directors are seeking approval of the LTIP and the amendment to the Option Plan at a General Meeting to be held at 9.00 a.m. at the offices of CMS Cameron McKenna LLP, Mitre House, 160 Aldersgate Street, London EC1A 4DD on 29 October 2010.

 

PuriCore Value Sharing Plan (LTIP)

The LTIP allows the creation of an award pool of 15% of the amount by which the market capitalisation of the Company exceeds £35 million on 30 September 2012. This award pool will be allocated amongst the participants at a pre-determined rate and is intended to be satisfied through a combination of new ordinary shares and cash. To implement the LTIP, the Option Plan is proposed to be amended to exclude the issue of any share awards under the LTIP from the Option Plan dilution limit.

 

PuriCore will realise short-term cash savings from the implementation of the LTIP as some participants are accepting reductions in cash-based compensation-for the term of the LTIP-in exchange for participation in the LTIP. These reductions include foregoing employer retirement plan contributions and waiving rights to the annual bonus scheme, for those participants who are entitled to these benefits, and certain participants taking an approximate 17% reduction in basic salary. Further, all participants must waive their rights to existing share option grants, whether vested or unvested.

 

A summary of the LTIP and a summary of the proposed amendment to the Option Plan is set out in the Circular.

 

Background to the PuriCore Value Sharing Plan

The Remuneration Committee of the Board of Directors (the "Remuneration Committee") believes the LTIP is an appropriate tool to motivate the participants to achieve the Company's sales growth and profitability goals, and to deliver significant value to shareholders in terms of market capitalisation increase. The Remuneration Committee is confident that the senior executive team charged with delivering the Company's goals is focused and that the strategies being implemented should allow the Company to meet its goals on an accelerated basis. Aligning the senior executive remuneration strategy with the Company's business goals and with the interests of shareholders is critical. The Remuneration Committee believes the LTIP does this in the following ways:

 

·; incentivises the participants to focus on strategies and tactics with a common goal of creating shareholder wealth by increasing market capitalisation;

 

·; establishes a challenging market capitalisation hurdle of £35 million (compared with the current market capitalisation of approximately £13 million) below which participants receive no pay-out;

 

·; provides a short-term (24-month) period for delivering on the Company's goals; and

 

·; offers flexibility in the type of senior executive remuneration (shares or cash), which the Remuneration Committee can utilise based on the financial and cash position of the Company at the time of the award.

 

A copy of the Circular and related form of proxy have been submitted to the National Storage Mechanism and will shortly be available for inspection. The Notice of General Meeting will shortly be available on the Company's website.

 

Enquiries:

 

Financial Dynamics

PuriCore

Susan Quigley

Chris Wightman

Ben Brewerton

Executive Chairman

+44 (0) 20 7831 3113

+44 (0) 20 7290 3440

 

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitisation. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEALEFFSEEFFF
Date   Source Headline
30th Jul 20087:04 amRNSPuriCore Wins Food Safety Con
30th Jul 20087:02 amRNSTrading Update
30th Jul 20087:00 amRNSPlacing and Open Offer
2nd Jul 20087:00 amRNSAwarded Contract
1st Jul 20087:00 amRNSPatent Decision and Debt Fina
26th Jun 200811:34 amRNSAGM Statement
19th Jun 20087:00 amRNSPiper Jaffray European Confer
9th Jun 20087:00 amRNSNatural Resources & Infrastru
2nd Jun 20087:00 amRNSAnnual Report and Accounts
27th May 20087:00 amRNSAnnual Information Update
20th May 20083:48 pmRNSHolding(s) in Company
14th May 200812:19 pmRNSHolding(s) in Company
13th May 20089:07 amRNSDirector/PDMR Shareholding
1st May 200810:06 amRNSDirector/PDMR Shareholding
30th Apr 20084:01 pmRNSDirector/PDMR Shareholding
29th Apr 20087:01 amRNSInterim Management Statement
29th Apr 20087:01 amRNSFinal Results
23rd Apr 20087:01 amRNSPresent Clinical Data
3rd Apr 20087:00 amRNSNotice of Results
21st Feb 20084:20 pmRNSNotice of Interest in Shares
21st Feb 20087:01 amRNSDirector/PDMR Shareholding
20th Feb 20087:01 amRNSTrading Update
20th Feb 20087:01 amRNSAcquisition Agreement for IP
8th Feb 20082:26 pmRNSHolding(s) in Company
6th Feb 20088:31 amRNSBlocklisting Interim Review
6th Feb 20088:04 amRNSSenior Independent Director
1st Feb 20088:48 amRNSVoting rights
23rd Jan 20087:00 amRNSResearch Update
11th Jan 20087:00 amRNSRe: Food Retail Contract
21st Dec 200711:36 amRNSHolding(s) in Company
10th Dec 20077:01 amRNSAdditional US Patent
23rd Nov 20075:52 pmRNSHolding(s) in Company
25th Oct 200712:00 pmBUSPuriCore Presenting at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
25th Oct 20077:00 amRNSPresenting at Conference
17th Oct 200712:00 pmBUSPuriCore Arranges New $20 Million Borrowing Facility
17th Oct 20077:00 amRNSArranges Borrowing Facility
12th Oct 20078:46 amRNSFCSI Product of the Year
11th Oct 20074:35 pmBUSSterilox Food Safety System Named FCSI Product of the Year
8th Oct 200712:00 pmBUSPuriCore Receives US Patent on Wound Therapy Method
8th Oct 20077:00 amRNSReceives US Patent
24th Sep 20077:03 amRNSRe: Wound Therapy System
24th Sep 20077:01 amRNSInterim Results
5th Sep 20074:14 pmRNSHolding(s) in Company
4th Sep 20077:01 amRNSBlocklisting Applications
31st Aug 20077:01 amRNSBlocklisting Interim Review
24th Jul 20076:24 pmRNSHolding(s) in Company
24th Jul 20079:32 amRNSDirector's Interest
23rd Jul 20077:01 amRNSTrading Update
18th Jun 200712:00 pmBUSAdditional Studies Demonstrate PuriCore's Sterilox Solution Effective against Major Outbreak Pathogens
18th Jun 20077:02 amRNSResearch Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.